Comparing two drug combinations for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests two different drug combinations for people with advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if one combination works as well as the other, potentially offering a new option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have colorectal cancer that cannot be removed by surgery.
- Your cancer has progressed or you could not tolerate at least two prior chemotherapy regimens (including fluoropyrimidine, oxaliplatin, and irinotecan) plus targeted therapy (anti-VEGF or anti-EGFR).
- You have at least one measurable tumor (can be seen on scans).
- You are able to swallow oral tablets or capsules.
- You have a life expectancy of at least 12 weeks and are generally active (ECOG 0-1).
- Your blood counts and organ function are adequate (e.g., hemoglobin ≥ 9 g/dL, creatinine clearance ≥ 60 mL/min).
- You have not had prior treatment with trifluridine/tipiracil, fruquintinib, or similar drugs (like regorafenib).
- You are not pregnant or breastfeeding, and you agree to use effective contraception if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—tucidinostat, sintilimab, and bevacizumab—for people with a specific type of advanced colorectal cancer (MSS or pMMR) that has gotten worse after standard treatments. The goal is to see if this new mix can help shrink or slow the tumor.
This trial tests a combination of two medications, fruquintinib (a targeted drug that stops blood vessel growth) and a chemotherapy pill called tegafur/gimeracil/oteracil (often used after standard chemo has stopped helping). The goal is to see if this combination can help control advanced colorectal cancer that has not responded to at least two prior treatments.
This trial compares two different drug combinations for people with colorectal cancer that has spread and has already been through one round of chemotherapy. One combination uses a newer targeted pill (fruquintinib) while the other uses a standard targeted medicine (bevacizumab), both with chemotherapy. The goal is to see which approach works better as a second-line treatment.
This trial tests two different drug combinations for people with advanced bowel cancer that has a specific genetic change (RAS mutation) and has already been treated with one type of chemotherapy. The goal is to see if one combination works better than the other.
This trial tests a two-drug combination (trifluridine/tipiracil plus regorafenib) against a standard pair (trifluridine/tipiracil plus bevacizumab) for people with advanced colorectal cancer that has stopped responding to prior treatments. It aims to find which combination works better.
This trial tests whether adding TAS-102 to fruquintinib works better than fruquintinib alone for people with advanced colorectal cancer that has stopped responding to other treatments.
Hear when a new Refractory Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.